Report - Kriterien für Behandlungswechsel in onkologischen Studien · Erstautor Indikation Zeitpunkt Kontrolle Neu N Crossover (%) RR PFÜ ÜLZ Miller, 2012 Lunge, NSCLC, EGFR+ ... Ipilimumab

Select PornographicDefamatoryIllegal/UnlawfulSpamOther Terms Of Service ViolationFile a copyright complaint

Please pass captcha verification before submit form